Back to Trials
NCT07516964NARecruiting

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Meyer Children's Hospital IRCCS

Start Date

6/10/2025

Completion Date

10/1/2036

Summary

Nephrotic syndrome is a kidney condition that mainly affects children and is characterized by high levels of protein in the urine, low levels of protein in the blood, and swelling. While many children respond well to steroid treatment, a large proportion experience relapses or become dependent on therapy. In some cases, the disease does not respond to standard treatments and may progress to chronic kidney disease. Recent research suggests that, in addition to genetic factors, immune system mechanisms may play a key role in the development and progression of nephrotic syndrome. In particular, some patients produce autoantibodies against nephrin, an essential protein of the kidney filtration barrier. These autoantibodies may be associated with disease activity and treatment response. The aim of this study is to investigate the presence of anti-nephrin autoantibodies in children with nephrotic syndrome and to better understand their role in disease mechanisms and clinical outcomes.The study will also explore the presence of other autoantibodies targeting components of the glomerular filtration barrier. The study will use advanced laboratory techniques, including blood tests and detailed analysis of kidney biopsy samples, to identify these antibodies and their relationship with kidney structure and function. By integrating laboratory findings with clinical data, this study aims to improve the understanding of nephrotic syndrome and support the development of more personalized diagnostic and therapeutic strategies, with the goal of improving patient outcomes and reducing unnecessary or ineffective treatments.

Eligibility Criteria

Age Range: No minimum to 99 years

Inclusion Criteria: * Pediatric and adult patients with a diagnosis of podocytopathy * Patients with nephrotic syndrome and/or histological diagnosis of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy (CG), or diffuse mesangial sclerosis (DMS) * Both newly diagnosed (incident) patients and patients already under follow-up at participating centers * Availability of clinical data from medical records (including paper and/or electronic records, laboratory reports, and discharge summaries) * Availability of biological samples (e.g., blood and/or renal biopsy), if collected as part of routine clinical care * Signed informed consent by the patient or legal guardian (and assent when applicable) Exclusion Criteria: * Refusal or inability of the patient, parents, or legal guardian to provide informed consent * Lack of sufficient clinical data or unavailable biological samples required for the study

Interventions

OTHER

Serum and renal tissue analysis

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Nephrotic Syndrome With Edema (Diagnosis)Minimal Change Nephrotic SyndromeFocal Segmental Glomerulosclerosis (FSGS)Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Locations

Mayo Clinic

Rochester, Minnesota 55902

United States

Ludwig-Maximilians Universitat

München,

Germany

Ospedale Santa Maria Annunziata

Bagno a Ripoli, Firenze

Italy

Meyer Children's Hospital IRCCS

Florence, FIRENZE 50139

Italy

IRCCS Azienda Ospedaliero - Universitaria

Bologna,

Italy

Azienda Ospedaliero Universitaria Careggi

Florence,

Italy

Ospedale S. Giovanni di Dio

Florence,

Italy

IRCCS Istituto Giannina Gaslini

Genova,

Italy

Azienda Ospedaliero-Universitaria di Parma

Parma,

Italy

Azienda Ospedaliero Universitaria Pisana

Pisa,

Italy

Ospedale Santo Stefano

Prato,

Italy

Azienda USL - IRCCS

Reggio Emilia,

Italy

Hospital General de México, Mexico City

Mexico City,

Mexico

Bellvitge University Hospital

Barcelona,

Spain